"ISGlobal is seeking a Junior Epidemiologist who is interested in working in the research activities of the ongoing projects of the Maternal Child and Reproductive Health Initiative, namely:
1) Improving Care through Azithromycin Research for Infants in Africa (ICARIA): A large-scale clinical trial, “An efficacy trial of the incremental mortality benefit of IPTi plus azithromycin” whose goal is to contribute to reduce child mortality in areas of high malaria and mortality burden in Sub-Saharan Africa.
The five-year project, funded by the Bill & Melinda Gates Foundation (BMGF) and co-funded by La Caixa Foundation is coordinated by ISGlobal. Through the project we will evaluate the impact on childhood mortality of azithromycin (AZi) plus intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTi-SP) administered through the Expanded Program on Immunisation (EPI) in Sierra Leone.
The ISGlobal-led consortium includes ISGlobal, as lead research and principal recipient and responsible to the funders for the implementation of the project, and national counterparts, namely, the Ministry of Health and Sanitation and the College of medicine and applied health sciences (COMAHS) in Sierra Leone. The consortium will work closely with other stakeholders such as the World Health Organization (WHO), UNICEF, and GAVI to ensure that all study outputs are met.
ISGlobal is the lead evaluation and research organization and is responsible for implementing a set of studies to generate evidence for global guidance on AZi administration and IPTi-SP. Specifically, ISGlobal will be responsible for designing and implementing the trial’s evaluation plan, as well as designing, analyzing and reporting the clinical and biological research studies to assess the efficacy and impact of the intervention. The ICARIA clinical trial will apply a community-based approach that fosters partnership and strengthens the dynamic link between communities and health facilities, especially for the most vulnerable people. A learning-driven approach will be employed throughout the project to generate sufficient evidence to inform WHO policy recommendations and future actions in Sierra Leone and similar sub-Saharan countries, in an effort to expand the intervention over the long-term.
2) “Multiple doses of IPTi” (MULTIPLY): MULTIPLY is a large-scale implementation project, which includes public and private European and African institutions aiming at maximising the delivery and uptake of Intermittent Preventive Treatment for malaria in infants (IPTi), to achieve full potential and effectiveness of this intervention. It will be carried out in selected country districts of Mozambique, Sierra Leone and Togo.
The 40 months project, is funded by the European and Developing Countries Trial Partnership (EDCTP) and coordinated by ISGlobal, the Barcelona Institute for Global Health, in partnership with the Institut de Recherche pour le Développement (IRD), France, the Fundaçao Manhiça (FM), Mozambique, the University of Lomé (UL), Togo, the University of Sierra Leone, Sierra Leone and the Medicines for Malaria Venture (MMV), Switzerland.
The consortium will work closely with the Ministries of Health in Sierra Leone, Togo and Mozambique, the World Health Organization (WHO) as well as other stakeholders, to ensure that all project outputs are met.
MULTIPLY will generate evidence for change and expand access to preventive chemotherapy for malaria in infants in sub Saharan Africa apply a community-based approach that fosters partnership and strengthens the dynamic link between communities and health facilities, especially for the most vulnerable people. A learning-driven approach will be employed throughout the project to generate sufficient evidence to inform WHO policy recommendations and future actions in each country, in an effort to expand the intervention over the long-term. "